ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,399.10
-0.12%
S&P ASX All Technology
3,865.80
-0.70%
Brent Oil
76.595
0.43%
US Dollar vs AUD
1.60067
0.26%
Bitcoin
102,679.47
0.60%
Pepperstone
Advertisement
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Biohaven Ltd (BHVN)

  7. Biohaven Ltd (BHVN) News

BHVN

Biohaven (BHVN)

Biohaven Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:BHVN
DateTimeSourceHeadlineSymbolCompany
14/01/202503:16Edgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
14/01/202503:15PR Newswire (US)Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation PoNYSE:BHVNBiohaven Ltd
13/01/202512:04GlobeNewswire Inc.Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC ProgramsNYSE:BHVNBiohaven Ltd
08/01/202509:54PR Newswire (US)Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNYSE:BHVNBiohaven Ltd
16/12/202423:30PR Newswire (US)Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program UpdatesNYSE:BHVNBiohaven Ltd
06/12/202423:30PR Newswire (US)Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual MeetingNYSE:BHVNBiohaven Ltd
25/11/202423:30PR Newswire (US)Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and ObesityNYSE:BHVNBiohaven Ltd
13/11/202408:16Edgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
13/11/202408:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:BHVNBiohaven Ltd
13/11/202408:05PR Newswire (US)Biohaven Reports Third Quarter 2024 Financial Results and Recent Business DevelopmentsNYSE:BHVNBiohaven Ltd
03/10/202406:18Edgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
03/10/202406:05PR Newswire (US)Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesNYSE:BHVNBiohaven Ltd
02/10/202406:06Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:BHVNBiohaven Ltd
01/10/202420:00PR Newswire (US)Biohaven Announces Pricing of $250 Million Public Offering of Common SharesNYSE:BHVNBiohaven Ltd
01/10/202407:29Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:BHVNBiohaven Ltd
01/10/202406:05PR Newswire (US)Biohaven Announces Proposed Public Offering of Common SharesNYSE:BHVNBiohaven Ltd
30/09/202421:30PR Newswire (US)Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of MigraineNYSE:BHVNBiohaven Ltd
24/09/202420:15IH Market NewsVisa Faces Monopoly Lawsuit; Meta Introduces Celebrity Voices for Chatbot; Stellantis on the Hunt for New CEONYSE:BHVNBiohaven Ltd
23/09/202423:11Edgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
23/09/202421:30PR Newswire (US)Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)NYSE:BHVNBiohaven Ltd
21/09/202409:09PR Newswire (US)Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar AtaxiaNYSE:BHVNBiohaven Ltd
17/08/202406:35Edgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
17/08/202406:31Edgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NYSE:BHVNBiohaven Ltd
17/08/202406:25Edgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
17/08/202406:21Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:BHVNBiohaven Ltd
10/08/202406:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:BHVNBiohaven Ltd
09/08/202406:17Edgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
09/08/202406:05PR Newswire (US)Biohaven Reports Second Quarter 2024 Financial Results and Recent Business DevelopmentsNYSE:BHVNBiohaven Ltd
29/05/202421:30PR Newswire (US)Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D DayNYSE:BHVNBiohaven Ltd
29/05/202421:15PR Newswire (US)Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial TumorsNYSE:BHVNBiohaven Ltd
 Showing the most relevant articles for your search:NYSE:BHVN

Your Recent History

BIT
UC5634
Unicredit Bank
BIT
Q00667
Leonteq Securities
BIT
UC2XV4
Unicredit Bank
BIT
NSCIT7310112
Republic of Poland
BIT
UC5CEA
Unicredit Bank
BIT
UB2Y63
UniCredit Bank
BIT
UC78Q9
Unicredit Bank
BIT
UC0ZZN
Unicredit Bank
BIT
UC4YBX
Unicredit Bank
BIT
X13E
Db X Trackers Ii iboxx S...
TG
A18U2F
United Parcel Service
BIT
UB0JNQ
UniCredit Bank
USOTC
BRTE
Brightec (CE)
TG
HV2AZG
UniCredit Bank
BIT
WFTC26
Finanzatech
BIT
UC1C34
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads